Skip to content

Acurx Pharmaceuticals, Inc.: 10-Q filed 2024-11-12

What Acurx Pharmaceuticals, Inc. reported in its quarterly report filed 2024-11-12 (fiscal Q3 2024): 20 published measures, 68 facts as tagged in accession 0001558370-24-015310.

This filing

Form
10-Q (quarterly report)
Filed
2024-11-12
Fiscal period
fiscal Q3 2024
Accession
0001558370-24-015310 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Acurx Pharmaceuticals, Inc. filings.

Reported measures

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2024-09-303,318,765USD
At 2023-12-313,042,438USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2024-09-302,663,994USD
At 2024-06-303,427,475USD
At 2024-03-315,998,592USD
At 2023-12-314,666,685USD
At 2023-09-303,934,673USD
At 2023-06-306,216,369USD
At 2023-03-315,311,439USD
At 2022-12-317,315,021USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2024-07-01 to 2024-09-30-2,821,597USD92
2024-01-01 to 2024-09-30-11,321,312USD274
2024-04-01 to 2024-06-30-4,121,826USD91
2024-01-01 to 2024-03-31-4,377,889USD91
2023-07-01 to 2023-09-30-3,114,981USD92
2023-01-01 to 2023-09-30-9,463,178USD273
2023-04-01 to 2023-06-30-3,445,240USD91
2023-01-01 to 2023-03-31-2,902,957USD90

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2024-01-01 to 2024-09-30-8,133,033USD274
2023-01-01 to 2023-09-30-5,603,107USD273

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2024-01-01 to 2024-09-306,421,409USD274
2023-01-01 to 2023-09-303,543,685USD273

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2024-09-30-64,540,165USD
At 2023-12-31-53,218,853USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2024-07-01 to 2024-09-3016,363,473shares92
2024-01-01 to 2024-09-3015,907,778shares274
2023-07-01 to 2023-09-3013,005,128shares92
2023-01-01 to 2023-09-3012,282,004shares273

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2024-07-01 to 2024-09-3016,363,473shares92
2024-01-01 to 2024-09-3015,907,778shares274
2023-07-01 to 2023-09-3013,005,128shares92
2023-01-01 to 2023-09-3012,282,004shares273

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2024-07-01 to 2024-09-30-0.17USD/shares92
2024-01-01 to 2024-09-30-0.71USD/shares274
2023-07-01 to 2023-09-30-0.24USD/shares92
2023-01-01 to 2023-09-30-0.77USD/shares273

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2024-07-01 to 2024-09-30-0.17USD/shares92
2024-01-01 to 2024-09-30-0.71USD/shares274
2023-07-01 to 2023-09-30-0.24USD/shares92
2023-01-01 to 2023-09-30-0.77USD/shares273

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2024-01-01 to 2024-09-302,256,712USD274
2023-01-01 to 2023-09-302,373,242USD273

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2024-09-305,982,759USD
At 2023-12-317,709,123USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2024-09-303,318,765USD
At 2023-12-313,042,438USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2024-07-01 to 2024-09-302,821,597USD92
2024-01-01 to 2024-09-3011,321,312USD274
2023-07-01 to 2023-09-303,114,981USD92
2023-01-01 to 2023-09-309,463,178USD273

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2024-07-01 to 2024-09-301,198,184USD92
2024-01-01 to 2024-09-304,578,777USD274
2023-07-01 to 2023-09-301,348,985USD92
2023-01-01 to 2023-09-304,100,954USD273

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2024-09-3016,770,378shares
At 2023-12-3114,468,229shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2024-09-305,762,564USD
At 2023-12-317,474,188USD
At 2023-09-307,052,329USD
At 2022-12-319,111,751USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2024-09-3067,187,389USD
At 2023-12-3157,871,070USD

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

PeriodValueUnitDays
2024-01-01 to 2024-09-30-11,321,312USD274
2023-01-01 to 2023-09-30-9,463,178USD273

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2024-07-01 to 2024-09-301,623,413USD92
2024-01-01 to 2024-09-306,742,535USD274
2023-07-01 to 2023-09-301,765,996USD92
2023-01-01 to 2023-09-305,362,224USD273

Inspect the source

Entity
Acurx Pharmaceuticals, Inc. / CIK 0001736243
Captured
2026-09-21T17:25:29.911Z
SEC response SHA-256
3ff72a27b12e3bbf2238c568e6d540d3ffd8acf36c9060b3da0911bb5446b5e9

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001736243.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))